Protocol Ledger

NCT05183984 · Phase II · RECRUITING

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

Interventional Phase II clinical trial protocol NCT05183984 sponsored by ARCAGY/ GINECO GROUP in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-02-01 Enrollment: 390 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05183984
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)390 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05183984
Protocol FieldVerified Registry Value
NCT IdentifierNCT05183984
Consolidated Lead SponsorARCAGY/ GINECO GROUP
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment390 participants (ESTIMATED)
Registered Start Date2022-02-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05183984
Hospital Research SiteLocationSite Profile
Institut BergoniéBordeaux, FranceOpen Hospital Dossier ->
Centre François BaclesseCaen, FranceOpen Hospital Dossier ->
Centre Jean PerrinClermont-Ferrand, FranceOpen Hospital Dossier ->
Centre Georges-François LeclercDijon, FranceOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI